Compare QUIK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUIK | SGHT |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.8M | 235.0M |
| IPO Year | 1997 | 2021 |
| Metric | QUIK | SGHT |
|---|---|---|
| Price | $16.51 | $4.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $11.00 | $9.08 |
| AVG Volume (30 Days) | ★ 376.6K | 312.1K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | $20,112,000.00 | ★ $77,363,000.00 |
| Revenue This Year | $75.17 | $11.67 |
| Revenue Next Year | $16.04 | $10.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.80 | $2.74 |
| 52 Week High | $16.89 | $9.24 |
| Indicator | QUIK | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 73.88 | 58.92 |
| Support Level | $5.67 | $3.29 |
| Resistance Level | N/A | $5.25 |
| Average True Range (ATR) | 1.24 | 0.28 |
| MACD | 0.35 | 0.06 |
| Stochastic Oscillator | 90.67 | 50.68 |
QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.